Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of CD19/CD20 CAR/TRuC-T in Relapsed/Refractory B-Cell Lymphoma

NCT07508605 is registered in ClinicalTrials.gov with Shenzhen University General Hospital as lead sponsor.

NCT NCT07508605
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07508605 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of CD19/CD20 CAR/TRuC-T in Relapsed/Refractory B-Cell Lymphoma
Lead sponsor
Shenzhen University General Hospital
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 1, 2025
Completion date
December 30, 2027
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory b-cell lymphoma